



57th Annual

# American Pancreatic Association (APA) Annual Meeting

December 9–12, 2026  
Hyatt Regency Resort & Spa  
Huntington Beach, California

## Official Scientific Schedule

*Program subject to change. All times in the local timezone (PST).*

Wednesday, December 9, 2026

### Pre-Meeting Symposium

Artificial Intelligence in Pancreatic Disease — APA 2026 Pre-Meeting  
Course Directors: Sohail Husain, MD & Shounak Majumder, MD

7:00–8:00 am

Breakfast and Registration

8:00–8:10 am

Opening Remarks and Overview

Sohail Husain, MD | Stanford University, Stanford, CA

8:10–9:15 am

Foundations of AI in Biomedicine

Moderators: Anne Marie Lennon, MD, PhD & Shounak Majumder, MD

8:10–8:30 am

Reinventing Medicine with AI: Ethics and First Principles

Micky Tripathi, PhD | Mayo Clinic, Rochester, MN.

**8:30–8:50 am**

**AI Co-Scientists and Other Agents**

Gary Peltz, MD, PhD | Stanford University, Stanford, CA

**8:50–9:15 am**

**Panel Discussion**

**9:15–10:45 am**

**AI in Pancreatic Imaging: From Detection to Prediction**

Moderators: Elif Keles, MD, Andrew Trout, MD, & Temel Tirkes, MD

**9:15–9:30 am**

**Charting the Evolution of AI in Pancreatic Radiology: Past Milestones and Present Innovations**

Eugene Koay, MD, PhD | MD Anderson Cancer Center

**9:30–9:45 am**

**Predicting Future Pancreatic Cancer Using CT scans: Myth or Reality?**

Qi Zhang, MD | Zhejiang University, China

**9:45–10:00 am**

**AI in Pancreatic MRI: Addressing Clinical Translation Barriers**

Ulas Bagci, PhD | Northwestern University, Evanston, IL

**10:00–10:15 am**

**Emerging AI Applications in Pancreatic EUS**

Michael Wallace, MD | Mayo Clinic, Jacksonville.

**10:15–10:45 am**

**Panel Discussion**

**10:45–11:00 am**

**Coffee Break**

**11:00 am–12:00 pm**

**Digital Pathology and Genomics: Leveraging AI for Precision Pancreatology**

Moderators: Huamin Wang, MD, PhD & Aatur Singhi, MD

**11:00–11:15 am**

**Dissecting Pancreatic Cancer Heterogeneity: Single-Cell, Spatial, and AI Approaches**

Aristotelis Tsirigos, PhD | NYU Grossman School of Medicine

**11:15–11:30 am**

**AI-Based 3D Reconstruction of the Human Pancreas**

Ashley Lynn Kiemen, PhD | Johns Hopkins University, Baltimore, MD

**11:30–11:45 am**

**AI-Based Histological Biomarkers for Pancreatic Cancer Chemotherapy Selection**

Andrew E. Hendifar, MD | Cedars-Sinai

**11:45 am–12:00 pm**

**Panel Discussion**

12:00–1:00 pm

Lunch

Networking

1:00–2:30 pm

Innovators in Digital Pancreatology: Short Pitches Highlighting High-Impact Projects

Moderators: Faysal Sohail & Crystal Kaya | Industry Leader

1:05–1:15 pm

Session Introduction and Overview

1:15–1:25 pm

Leveraging AI for Identification of High-Risk Populations with Familial and Germline PDAC Predisposition

Anup Mishra, MD | Mayo Clinic, Rochester, MN

1:25–1:35 pm

Applying AI to Endomicroscopy for Risk Stratification of Pancreatic Cysts

Somashekar G. Krishna, MD | Ohio State University Wexner Medical Center.

1:35–1:45 pm

EHR Build

Shounak Majumder, MD | Mayo Clinic, Rochester

1:45–1:55 pm

Real-World EHR-Based Pancreatic Cancer Risk Prediction Trial

Bechien Wu, MD | Kaiser Permanente

1:55–2:05 pm

AI Abstract: Toward Feature-Guided Risk Stratification of Main-Duct IPMN using MRI-Based Deep Learning

Eminur Sen Tasci, MD | Northwestern University, Evanston, IL

2:05–2:15 pm

AI Abstract: AI-Guided Organoid Modeling of CFTR-Driven Pancreatitis

Paba Edisuriya, PhD | Cedars-Sinai Medical Center

2:15–2:30 pm

Moderator Feedback and Tips on Making a Successful Pitch

2:30–4:00 pm

AI Industry Keynote and Panel

Moderators: George Papachristou, MD, PhD, Jianbo Ni, MD, PhD, & Sohail Husain, MD

2:30–2:45 pm

AI Robotics in Hepatobiliary and Pancreatic Surgery

Brock Hewitt, MD | NYU Langone Health

2:45–3:00 pm

The Next Frontier of AI-Enhanced Pancreatic EUS

Venkata Akshintala, MD, PhD | Johns Hopkins University, Baltimore, MD

3:00–3:15 pm

The Future of AI

Faysal Sohail | Presidio Partners

**3:15–3:50 pm**

**Panel Discussion**

**3:50–4:00 pm**

**Synthesis & Closing Remarks**

Shounak Majumder, MD | Mayo Clinic

---

## **Hirshberg Symposium | 5:00–7:00 pm**

### **Immunology and Immunotherapy in Pancreatic Cancer**

Session Chair: Ashok K. Saluja, PhD & O. Joe Hines, MD

#### **Featured Lectures:**

**5:00–5:25 pm**

**The New Era of Cancer Vaccines: Treatment, Interception and the Convergence of Precision Medicine and Immunology**

Elizabeth Jaffee, MD | Johns Hopkins University

**5:30–5:55 pm**

**Advancing Strategies for Extended Survival in Pancreatic Cancer**

Baiyong Shen, MD, PhD, FACS | Ruijin Hospital, Shanghai

**6:00–6:25 pm**

**Featured Lecture: Tumor Microenvironment and Immunity**

Timothy Wang, MD | Columbia University, New York, NY

**7:00–9:00 pm**

**Presidential Reception**

## **Thursday, December 10, 2026**

**7:00–8:00 am**

**Registration**

**Posters & Breakfast**

**AbbVie Product Theater**

**8:00–10:00 am**

**10 Min–(8 min talk plus 2 min Q&A)**

### **Abstract-Driven Session: Pancreatitis**

**NFE2L1/Nrf1 promotes ferroptosis resistance in pancreatic acinar cells during pancreatitis by regulating glutathione synthesis.**

Zhe Cao, PhD — Harvard TH Chan School of Public Health

**Identification and Validation of a Serum Signature for the Early Stratification of Severe Acute Pancreatitis.**

Hanzhang Deng, MD — Biomarker Platform, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China

**Pharmacological Correction of CFTR Attenuates Experimental Chronic Pancreatitis.**

Tamara Madacsy, PhD — University of Szeged, Department of Translational Medicine, Szeged, Hungary

**Clinical Outcomes and Practice Variations in Pediatric Acute Pancreatitis Before and After the Release of Acute Pancreatitis Management Recommendations.**

Joshua Oarhe, BS — University of Nebraska Medical Center, Omaha, NE

**Humanized anti-PNLIP antibody rescues obesity-associated lethal acute pancreatitis in mice.**

Jiale Wang, MD, PhD — Mayo Clinic

**Insulin use and glycemic control in a U.S.-based cohort of adults with recurrent acute or chronic pancreatitis and diabetes mellitus.**

Melena Bellin, MD — University of Minnesota, Minneapolis, MN

**CD169<sup>+</sup> Macrophages Exacerbate Acute Pancreatitis by Functioning as Lipo-Inflammatory Amplifiers.**

Meng Jin, PhD — The First Affiliated Hospital, Zhejiang University School of Medicine

**Evaluation Of The Relationship Between Neural Sensitisation and Neuropsychological Alterations In Patients With Painful Chronic Pancreatitis.**

Abdul Rasheed Mohammed, Pharm.D — AIG Hospitals, India

**Protective Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Against Recurrent Acute Pancreatitis: A U.S. Population-Based Propensity-Matched Cohort Study Clinical Pancreatitis.**

Mustafa Arain, MD — University of Texas at Houston

**Protective Role of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Against Recurrent Acute Pancreatitis: A U.S. Population-Based Propensity-Matched Cohort Study.**

Mustafa Arain, MD — University of Texas Health, Houston, TX, USA

**10:00–10:30 am**  
**Break with Exhibitors**

**10:30–11:45 am**

**Beyond the Scalpel: Redefining the Limits of Pancreatic Cancer Surgery**

**10:30–10:45 am**

**The Surgeon's GPS: Precision Decision-Making in PDAC**

Christopher Wolfgang, MD, PhD | NYU Langone Health

**10:45–11:00 am**

**Timing is Everything: Optimizing Neoadjuvant Therapy and Surgery**

Susan Tsai, MD | Ohio State University, Columbus, OH

**11:00–11:15 am**

**Crossing the Line: Tackling Vascular Challenges in PDAC**

Christoph Michalski, MD | Heidelberg University

**11:15–11:30 am**

**Early Recurrence After Pancreatic Cancer Surgery: Can We Identify It Before the Scalpel?**

Ippei Matsumoto, MD, PhD | Kindai University

**11:30–11:45 am**

**Revising the Surgical Outlook: Converting Unresectable Tumors into Resectable Disease**

Nirav Thosani, MD | UT Health Houston, McGovern Medical School

**Frank Brooks Lecture | 11:45 am–12:15 pm**

**Distinguished Keynote Address**

**Fascinated by Chronic Pancreatitis: A Never-Ending Quest**

Prof. Atsushi Masamune, MD, PhD — Tohoku University, Japan

**12:15–2:00 pm**

**Lunch**

**Posters**

**Amgen Product Theater**

**Posters of Distinction**

**POD- 1 High versus gradually increasing energy nutrition in the early phase of acute pancreatitis (GOULASH): a multicentre double-blind randomised clinical trial**

Katalin Márta, MD, PhD — Semmelweis University

**POD- 2 Neoadjuvant Chemotherapy with or without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma: A Propensity Score-Matched Analysis**

Nathaniel F. Wu, BA — Massachusetts General Hospital, Harvard Medical School

**POD- 3 Multi-omics analyses reveals arachidonic acid influx-induced CD36<sup>hi</sup> monocytes exacerbate inflammation in hypertriglyceridemia acute pancreatitis**

Qiang Liu, PhD — Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, China

**POD- 4 ACAP1 Reshapes the Th1/Treg Landscape to Boost Neoadjuvant Chemotherapy-Induced Immune Response in Pancreatic Cancer**

Junhong Li, PhD — Chongqing General Hospital, Chongqing University, Chongqing, China

**POD- 5 Pain Response in Chronic Pancreatitis Patients Receiving Placebo: Systematic Review, Meta-Analysis, and Meta-Regression**

Tareq Alsaleh, MD — AdventHealth Orlando, Orlando, FL, USA

**POD- 6 ELF3-FOSL1 Defines a Prognostic Epithelial-Mesenchymal Continuum in Pancreatic Ductal Adenocarcinoma**

Vineet Kumar Gupta, PhD — University of Miami, Miami, FL, USA

**POD- 7 Notch Pathway and Chronic Pancreatitis**

Srikanth Iyer, PhD — University of Iowa Health Care, Iowa City, IA, USA

**POD- 8 Practice-Guideline Gap in the Surgical Management of Pancreatic Cancer with Liver Metastases**

Rene Mantke, MD — Brandenburg Medical School, University Hospital Brandenburg, Brandenburg, Germany

**POD- 9 Stroma-derived RSPO3 induced by IL-1 $\beta$  promotes intestinal mucosal repair in severe acute pancreatitis**

Zhongmei Tian, MD — Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

**POD- 10 Targeting AGE-Mediated Collagen Linearization and the MYH10-MTCH2 Mitochondrial Fusion Axis Reinvigorates CD8<sup>+</sup> T Cells and Sensitizes Pancreatic Cancer to PD-1/PD-L1 Blockade**

Yongsu Ma, MD — Peking University First Hospital, Beijing, China

**POD- 11 Health-Related Social Needs Are Associated with Pain Burden and Emergency Department Utilization in Chronic Pancreatitis**

Bryan Alvarez-Carcamo, BA — University of Michigan, Ann Arbor, MI, USA

**POD- 12 PAN-CODE: An Agentic AI Pipeline for PANcreatic Cancer COhort DETection**

Anup Kumar Mishra, PhD, MS — Mayo Clinic, Rochester, MN, USA

**POD- 13 Improving islet engraftment after total pancreatectomy with islet autotransplantation (TPIAT) utilizing native microvessels of human pancreas (NMVP): Signaling mechanisms that regulate islet microcirculation**

Krishna Kumar Samaga, MS — Nationwide Children's Hospital, Columbus, OH, USA

**POD- 14 Ferroptosis-Associated Transcriptomic Dysregulation in Pancreatic Ductal Adenocarcinoma: An Integrated FerrDb and GEO-Based Analysis**

Bhavani Gavara, MBBS — Cedars-Sinai Medical Center, Los Angeles, CA, USA

**POD- 15 From Healthy Pancreas to Chronic Disease: MRI Volumetry Reveals Pancreatic Atrophy Across the Pediatric Pancreatitis Spectrum**

Elif Keles, MD, PhD — Northwestern University Feinberg School of Medicine, Chicago, IL, USA

**POD- 16 Fatty Pancreas and Lymph Node Metastasis in Established Pancreatic Cancer: A Systematic Review and Meta-analysis**

Ana Lucia Valenzuela Garcia, MD — Faculty of Medicine, Universidad Durango Santander, Hermosillo Campus, Sonora, Mexico

**POD- 17  $\beta$ -Cell Reserve Depletion and Pancreatic Exocrine Insufficiency Jointly Impair Glucose Homeostasis in Patients with Chronic Pancreatitis**

Rulan Wang, MD — Shanghai Changzheng Hospital, Shanghai, China

**POD- 18 Diagnostic Yield Of Endoscopic Ultrasound-Guided Evaluation And Tissue Acquisition Of Pancreatic Lesions Up To  $\leq 10$ mm In Size**

Yara Salameh, MD — Mayo Clinic

**POD- 19 Immune-intrinsic PIN1 regulates CD4<sup>+</sup> T cell subtype balance in chronic pancreatitis.**

Vidhi Shah, PhD — Oregon Health & Science University, Portland, OR, USA

**POD- 20 RAGE as a Therapeutic Target to Regulate Anti-Tumor Immunity in the PDAC Tumor Microenvironment**

Maria Salcedo Noriega, BS — University of Iowa, Iowa City, IA, USA

**POD- 21 Plozasiran in Patients with Severe Hypertriglyceridemia: The SHASTA-3 and SHASTA-4 Pivotal Trial 12-Month Results**

Norman Lepor, MD — Arrowhead Pharmaceuticals

**POD- 22 Leveraging Glycemic Changes for Early Detection of Pancreatic Cancer in the National VA**

Tyger Lin, BS — Yale University School of Medicine, New Haven, CT

**POD- 23 CT-derived abdominal fat phenotype correlates with beta cell function following acute pancreatitis (AP): preliminary findings from the Diabetes Related to Acute Pancreatitis and its Mechanisms (DREAM) Study**

Guru Trikudanathan, MD — University of Minnesota Medical Center, Minneapolis, MN, USA

**POD- 24 A Stem Cell-Engineered Immune-Reconstituted PDAC Organoid Reveals CAF Lineage-Specific Therapeutic Vulnerabilities**

Yujie Li, PhD — Department of Physiology, School of Biomedical Sciences, Faculty of Medicine & Health, University of New South Wales, Sydney, NSW, Australia

**POD- 25 Nerandomilast ameliorates chronic pancreatitis via inhibiting pancreatic stellate cell activation and Th1-mediated inflammatory response**

Jiahui Zhang, PhD — Peking Union Medical College Hospital, Beijing, China

**POD- 26 Histopathology of Arterial Disease in Pancreatic Cancer: Opportunities for Therapy.**

Matthew Krell, MD — NYU Langone Health

**POD- 27 Network Propagation Supports Replicated Vitamin A Protection in Asparaginase-Associated Acute Pancreatitis**

Mayur Sarangdhar, PhD — Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

**POD- 28 Localized IFN- $\alpha$  Delivery by an Oncolytic Adenovirus Enhances Antitumor Immunity in Pancreatic Cancer**

Julia Davydova, MD, PhD — University of Minnesota, Minneapolis, MN, USA

**POD- 29 Neutrophil Stalling at Pancreatic Branch Points as a Driver of Microvascular Flow Arrest in Acute Pancreatitis**

Justin Clark, PhD — Mayo Clinic, Rochester, MN, USA

**POD- 30 Risk Stratification for Pancreatic Cancer Diagnosis Using Type 2 Diabetes Phenotypes, a Single-site Observational Retrospective Cohort Study**

Martin Arnoletti, MPH — Vanderbilt University School of Medicine, Nashville, TN, USA

**POD- 31 Primary Painless Chronic Pancreatitis: A Distinct Idiopathic-Enriched Phenotype with Under-Recognized Disease Burden**

Richu Ravikumar, MBBS — Johns Hopkins University School of Medicine, Baltimore, MD

**POD- 32 Adipocytes derived small molecules promote pancreatic cancer progression**

Ruohong Wang, PhD — NYU Grossman School of Medicine, New York, NY, USA

**POD- 34 Mesenchymal Stromal Cell-Derived Extracellular Vesicles Mitigate Acute Pancreatitis by Reprogramming Immune Responses and Inflammatory Cell Infiltration**

Hongjun Wang, PhD — Ralph H Johnson VA Medical Center, Charleston, SC, USA

**2:00–3:00 pm**

**The 30-Year Genome: Honoring Three Decades of Pancreatitis Breakthroughs**

**2:00–2:15 pm**

**PRSS1 Disease: What Have We Learned in 30 Years?**

David Whitcomb, MD, PhD | University of Pittsburgh, Pittsburgh, PA

**2:15–2:30 pm**

**Emerging Candidate Genes Driving Pancreatitis**

Boan Ji, MD, PhD | Mayo Clinic, Jacksonville

**2:30–2:45 pm**

**Does Genome-Wide Single Nucleotide Polymorphism (SNP) Genotyping in Pancreatitis Improve Clinical Decision Making?**

Maisam Abu El-Haija, MD | Cincinnati Children's Hospital Medical Center

**2:45–3:00 pm**

**Modeling Mutations: Pre-Clinical approaches to hereditary Pancreatitis**

Miklos Sahin-Toth, MD, PhD | UCLA

**Concurrent Session A | 3:00–4:15 pm**

**Session: When Pancreatitis Leaves Its Mark: Beyond the Acute Episode**

**3:00–3:15 pm**

**Role of GLP-1 Agonists in Pancreatitis and Metabolic Disease.**

Anna Casu, MD | AdventHealth

**3:15–3:30 pm**

**Management of Exocrine Pancreatic Insufficiency and Diabetes**

**3:30–3:45 pm**

**False Alarm or Early Failure? Deciphering Low Fecal Elastase with Normal Pancreatic Imaging**

Georgios Papachristou, MD | Ohio State Wexner Medical Center

**3:45–4:00 pm**

**Beyond the Pancreas: Bone Health in Pancreatitis**

Walter Park, MD | Stanford University, Stanford, CA

**4:00–4:15 pm**

**Disconnected Duct Syndrome – A Clinician's Perspective**

Nicholas Zyromski, MD | Indiana University School of Medicine

**Concurrent Session B | 3:00–4:00 pm**

**The Next Wave of PDAC Research: From Genomic Evolution to Systemic Cachexia.**

**3:00–3:15 pm**

**Reading the Tumor's Playbook: Evolution and Precision Therapy**

Prasenjit Dey, PhD | Roswell Park Comprehensive Cancer Center

**3:15–3:30 pm**

**Beyond the Guardian: New Vulnerabilities in p53 Biology**

Laura Attardi, PhD | Stanford University, Stanford, CA

**3:30–3:45 pm**

**The Hidden Engine of Cachexia: Immunity Meets Metabolism**

Mingyang Liu, MD | Peking Union Medical College Cancer hospital

**3:45–4:00 pm**

**When Fat Fights Back: Adipose Remodeling in Pancreatic Cachexia**

Iok In Christine Chio, PhD | Columbia University, New York, NY

**4:15–4:30 pm**  
**Break with Exhibitors**

**4:30–6:30 pm**

**Abstract-Driven Session: Pancreatic Cancer**

**Targeting the fibroinflammatory cell-cell interactions in pancreatitis and pancreatic cancer**

Yang Chen, PhD — The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**A Multimodal Fusion Model Predicts Regimen-Specific Survival and Guides Chemotherapy Selection in Pancreatic Ductal Adenocarcinoma**

Shulin Zhao, MD, PhD — Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

**CD105 Defines a Metabolically Distinct and Therapeutically Targetable Fibroblast Lineage in Human Pancreatic Ductal Adenocarcinoma**

Zaklina Kovacevic, PhD — University of New South Wales, Sydney, NSW, Australia

**Comparison of MRI and Endoscopic Ultrasound for the Evaluation of Pancreatic Cystic Lesions: Head-to-Head Same Cohort Comparison**

Saeed Soleymanjahi, MD, MPH — Mass General Brigham/ Harvard Medical School

**Chr19q13.2 Copy Number Amplification Generates ecDNA and Confers Chemotherapeutic Vulnerability in Pancreatic Cancer**

Ningning Niu, PhD — Ren Ji Hospital, Shanghai Cancer Institute, Shanghai Jiao Tong University School of Medicine, Shanghai, China

**Transcriptomic and DNA-Based Testing Improves Preoperative Classification of Pancreatic Cysts and Detection of Advanced Neoplasia**

Aatur Singhi, MD, PhD — University of Pittsburgh Medical Center, Pittsburgh, PA, USA

**Micro-CT analysis can distinguish features of PDAC: preliminary experience**

Kaisa Tyrväinen, MD — Tampere University Hospital, Tampere, Finland

**Deep Proteomics Driven Machine Learning Strategy Enables Early Detection of Pancreatic Cancer in High Risk Population with New-onset Diabetes**

Yongxing Du, MD — National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

**Tumour-derived small extracellular vesicles promote neutrophil extracellular traps formation and pancreatic cancer liver metastasis through an SREBP1-dependent CDK6 pathway**

Cancan Zhou, MD — The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

**AI-Derived Nuclear Morphometry on Routine Histopathology Improves Survival Prediction in Resected Pancreatic Ductal Adenocarcinoma (PDAC)**

Sovanlal Mukherjee, PhD — Mayo Clinic, Rochester, MN, USA

**Clinical Validation and Lead-Time Sensitivity of a Multi-Analyte Blood-Based Test for the Detection of Pancreatic Cancer in Individuals with New-Onset Diabetes**

Suresh Chari, MD — MD Anderson Cancer Center

**Neoadjuvant Endoscopic Ultrasound-Guided Radiofrequency Ablation for Pancreatic Ductal Adenocarcinoma: Surgical Safety and Pathologic Outcomes Clinical Pancreatic Cancer.**

Christiaan van der Weidan — University of Texas Health Sciences Center at Houston

7:00–8:00 pm  
Awards Reception

8:00– 10:00 pm  
Awards Dinner

Friday, December 11, 2026

7:00–8:00 am  
Registration, Posters and Breakfast  
Breakfast Mentoring Session (Sponsored by AbbVie)

**Cracking the KRAS Code: From Lab Bench to Bedside Success**

8:30–9:30 am

8:30–8:50 am

**RAS-302: Impact on the PDAC Treatment Paradigm**

Andrew Hendifar, MD | Cedars-Sinai

**8:50–9:10 am**

**Variant-Specific Targeting in Pancreatic Cancer**

Ignacio Garrido-Laguna, MD, PhD | Moffitt Cancer Center

**9:10–9:30 am**

**Clinical Development of KRAS-Directed Therapies in Pancreatic Cancer**

Liwei Wang, MD, PhD | Renji Hospital, Shanghai

**9:30–10:15 am**

**Revmed Product Theater**

**10:15–10:45 am Break**

**Concurrent Session A | 10:45 am–12:00 pm**

**Ras Signaling and Therapy in Pancreatic Cancer**

**10:45–11:00 am**

**Targeting KRAS in the Clinic: Next-Generation Inhibitors, Resistance, and Combination Strategies**

Devalingam Mahalingam, MD, PhD | Northwestern University, Evanston, IL

**11:00–11:15 am**

**Starving the Beast: Targeting KRAS-Driven Metabolic Hunger**

Cosimo Commisso, PhD | Sanford Burnham Prebys

**11:15–11:30 am**

**From Mutations to Medicine: Precision Trials in KRAS-driven Pancreatic Cancer**

Christos Fountzilas, MD | Roswell Park Comprehensive Cancer Center

**11:30–11:45 am**

**The Nano Route: Novel Drug Delivery Systems in Pancreatic Cancer**

Subhash Chauhan, PhD | South Texas Center of Excellence in Cancer Research, UT Rio Grande Valley

**11:45 am–12:00 pm**

**Q&A Discussion**

**Concurrent Session B | 10:45 am–12:00 pm**

**IgG4-Related Pancreatobiliary Disease**

**10:45–11:00 am**

**Pathophysiology of IgG4-Related Disease: Implications for the Therapeutic Pipeline**

Yasmin Hernandez-Barco, MD | Massachusetts General Hospital

**11:00–11:15 am**

**Diagnostic Pitfalls of Type 1 Autoimmune Pancreatitis**

Suresh Chari, MD | MD Anderson Cancer Center

**11:15–11:30 am**

**Treatment of IgG4-Related Disease: Available and Emerging Options for Induction and Maintenance Therapy**

Phil Hart, MD | The Ohio State University

**11:30–11:45 am**

**IgG4-Related Sclerosing Cholangitis: How to Distinguish from PSC and Cholangiocarcinoma**

James Buxbaum, MD | USC Keck School of Medicine

**11:45 am–12:00 pm**

**Q&A Discussion**

12:00–2:00 pm

Lunch

Posters

**APOD- 35 Same-Day Versus Staged EUS and ERCP in Pancreatic Cancer: Hospital Use, Safety, and Mortality**  
Himsikhar Khataniar, MD — The University of Texas Health Science Center at Houston

**POD- 36 Malignant Cell Specific Transcriptomic Programs Predict Differential Benefit from First Line Chemotherapy Regimens in Pancreatic Cancer**

Yanjing Li, PhD — Shanghai Cancer Institute, Shanghai, China

**POD- 37 Feasibility and Preliminary Efficacy of a Coach-free Web-Based Self-Management Program for Painful Chronic Pancreatitis: A Pilot Trial**

Jorge Machicado, MD, MPH — University of Michigan, Ann Arbor, MI, USA

**POD- 38 Keratin 17-Driven Inflammatory Signaling as a Therapeutic Target for Immune Evasion in Pancreatic Cancer**

Monisankar Ghosh, PhD — Stony Brook University, Stony Brook, NY

**POD- 39 Systemic Lipid Dysregulation Drives a Continuous Trajectory from Exocrine Inflammation to Endocrine Collapse: A Dual-Cohort Clinical and Proteomic Study**

Yi-man Wang, MD — Shanghai Changzheng Hospital, Shanghai, China

**POD- 40 Implementation of an Early Detection Program for Pancreatic Cancer Using Electronic Health Record-Based Risk Prediction Models**

Tiffany Luong, MPH — Southern California Permanente Medical Group, Pasadena, CA, USA

**POD- 41 BACH1 MARKS THE PANCREATITIS-TO-NEOPLASIA TRANSITION AND LINKS TOXIC CARCINOGENS IN PANCREATIC ACINAR-TO-DUCTAL METAPLASIA**

Varunkumar Krishnamoorthy, PhD — University of Miami Miller School of Medicine, Miami, FL, USA

**POD- 42 Leptotrichia wadei remodels pancreatic and hepatic microenvironments to promote PDAC liver metastasis**

He Ren, PhD — Qingdao Medical College, Qingdao University, Qingdao, Shandong, China

**POD- 43 21-Oxo-Docosanoic Acid, a Fatty Acid  $\omega$ -Oxidation-Derived Metabolite, Marks Compensatory Lipid Oxidation and Predicts Non-Mild Acute Pancreatitis**

Jianing Li, MD — Peking Union Medical College Hospital, Beijing, China

**POD- 44 Classical subtype identifies PDAC patients with favorable outcome under RAAS inhibition**

Niels Siegel, MD — Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA

**POD- 45 Full Islet Function, Higher C-peptide, and Lower Hemoglobin A1c are Associated with Reduced Risk of Microvascular Complications in Long-Term Follow Up After Total Pancreatectomy and Islet Autotransplantation (TPIAT)**

Melena Bellin, MD — University of Minnesota, Minneapolis, MN, USA

**POD- 46 Deciphering the Tumor-Stroma-Islet Crosstalk: ANGPTL4 as a Novel Mechanic Biomarker for Pancreatic Cancer-Associated Diabetes**

Yongxing Du, MD — Peking Union Medical College Hospital, Beijing, China

**POD- 47 Sarcopenia as a Marker of Outcomes After Surgery for Chronic Pancreatitis**

Dhruv Patel, MD — University of North Carolina, Chapel Hill, NC, USA

**POD- 48 Automated Multidimensional Assessment of Laparoscopic Camera Navigation Quality in Pancreatic Surgery Using Spatiotemporal Instrument Tracking**

Xianlong Du, MD — Peking Union Medical College Hospital, Beijing, China

**POD- 49 Integrative Genetic and Epigenomic Analyses Prioritize Functional Non-coding Variants Underlying Pancreatitis Susceptibility**

Jun Xu, PhD — University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

**POD- 50 Clinical Validation and Lead-Time Sensitivity of a Multi-Analyte Blood-Based Test for the Detection of Pancreatic Cancer in Individuals with New-Onset Diabetes**

Suresh Chari, MD — The University of Texas MD Anderson Cancer Center, Houston, TX, USA

**POD- 51 Different-Dose Glucocorticoid Regimens for Induction Therapy in Type 1 Autoimmune Pancreatitis: Interim Results of a Randomized Controlled Trial**

Yingyun Yang, MD — Peking Union Medical College Hospital, Beijing, China

**POD- 52 Divergent paths from early PDAC heterogeneity: an OXPHOS-driven gastric-like fate and a mechano-dependent progenitor fate**

Jing Xue, PhD — Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

**POD- 53 Transition readiness after total pancreatectomy with islet autotransplantation: A matched comparison with type 1 diabetes**

Benny Moss, MD — Nationwide Children's Hospital, Columbus, OH, USA

**POD- 54 Integrated Spatial Architecture-Based Prognostic Stratification in Pancreatic Ductal Adenocarcinoma**

Dan Cao, PhD — West China Hospital, Sichuan University, Chengdu, Sichuan, China

**POD- 55 Disease Mapping in Pancreatic Ductal Adenocarcinoma with 68Ga-FAPI-46 PET: A Systematic Review and Meta-Analysis**

Baloy Talukdar, MD — Mayo Clinic, Rochester, MN, USA

**POD- 56 Tumor cell CHK $\alpha$ -driven nicotinamide metabolic reprogramming in neutrophils modulates immunotherapy response in pancreatic cancer**

Wenchao Xu, PhD — Peking Union Medical College Hospital, Beijing, China

**POD- 57 Artificial Intelligence in Pancreatic Cancer: Global Disparities in Research Productivity, Authorship, and Scholarly Impact**

Arjun Chatterjee, MD — Cleveland Clinic, Cleveland, OH, USA

**POD- 58 Predicting Organ Failure in Older Adults With Acute Pancreatitis: The Prognostic Value of Admission SIRS**

Simon Krakovsky, MD — University of Southern California, Los Angeles, CA, USA

**POD- 59 Short-Term Outcomes of Vascular Resection in Pancreatic Cancer Surgery: A Nationwide Real-World Study From Germany**

Artur Rebelo, MD — University Hospital Halle (Saale), Martin Luther University Halle-Wittenberg, Halle (Saale), Germany

**POD- 60 Cancer cachexia-induced muscle wasting drives immune evasion through immunosenescence in pancreatic cancer**

Zhijun Zhou, MD — The Affiliated Hospital of Qingdao University, Qingdao, China

**POD- 61 Clinical Yield of Risk-Based Imaging Surveillance Using a Machine Learning Prediction Model for Pancreatic Cancer**

Rebecca Moon, MD — Kaiser Permanente, Pasadena, CA, USA

**POD- 62 Dynamic Short-Term Prediction of Pancreatic Cancer Recurrence Using Postoperative CA19-9 Kinetics: A Landmarking Machine Learning Approach**

Takehiro Fujii, MD, PhD — Mie University, Tsu, Mie, Japan

**POD- 63 ZIP4 Loss Triggers Mitochondrial dsRNA Stress and ADAR-Dependent Vulnerability in Pancreatic Cancer**

Xinyu Yang, PhD — The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

**POD- 64 Risk and Predictors of Insulin Dependence Following Partial Pancreatectomy**

Arjun Chatterjee, MD — Cleveland Clinic, Cleveland, OH, USA

**POD- 65 Diagnostic Accuracy of a Four-miRNA Panel for Early Detection of Pancreatic Cancer: A Multicenter, Double-Blind Diagnostic Trial**

Gary Xiao, MD, PhD — Kante (Shenzhen) Biotechnologies Co., Ltd., Shenzhen, China

**POD- 66 Integrating Clinical Note Text and Laboratory Trends for Early Pancreatic Cancer Detection in the Electronic Health Record**

Jianfu Li, PhD — Mayo Clinic, Rochester, MN, USA

**POD- 67 Construction of a Prognostic Model for Pancreatic Ductal Adenocarcinoma Based on Cancer-Associated Fibroblast Signature Genes and Functional and Mechanistic Investigation of GJB2**

Zichen Pan, PhD — Peking University First Hospital, Beijing, China

**POD- 68 Pre-diagnosis physical activity is a modifiable factor in pancreatic cancer survival independent of obesity status**

Nikita Patel, BS — Kaiser Permanente Southern California, Pasadena, CA, USA

**POD- 69 Diagnostic Accuracy of MUST, NRS-2002, and PG-SGA Against GLIM-Defined Malnutrition in Patients Undergoing Resection-Intent Surgery for Pancreatic Ductal Adenocarcinoma**

Miguel Borges, MD — Botton-Champalimaud Pancreatic Cancer Centre, Lisbon, Portugal

**POD- 70 Intratumoral Bacteria in Pancreatic Ductal Adenocarcinoma: Toward a Reproducible Microbial Signature and Its Putative Role in Immune Modulation**

Xiangsheng Huang, PhD — University of Texas Health Science Center at Houston, Houston, TX, USA

**POD- 71 Pancreatectomy 30 Day Outcomes with Disrupted Enhanced Recovery Implementation: A Retrospective Review of the ACS NSQIP Database**

Sharon Baoas, DNP — New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, USA

**2:00–2:15 pm**

**APA Business Meeting**

**Paul Webster Lecture | 2:15–2:45 pm**

**Distinguished Keynote Address**

**Artificial Intelligence in Medicine: The Present, the Promise, and the Preservation of the Physician**

Darwin Conwell, MD | University of Kentucky

**Concurrent Session A | 2:45–4:15 pm**

**Abstract-Driven Session: Pancreatitis**

**Acinar-to-Ductal Metaplasia Contributes to Chronic Pancreatitis Fibrosis via the EFNB1-EPHB2 Axis and Activation of GLI1+ Stromal Cells.**

Chenxiao Liu, MD — Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

**Obexelimab, a B cell inhibitor, in IgG4-Related Disease, Including Patients with Pancreatobiliary Involvement: Results from the Phase 3 INDIGO Trial**

Audrey Wells, PhD — Zenas BioPharma, Waltham, MA, USA

**Uncovering Macrophage Aox1 and IFN $\gamma$  as a Novel Therapeutic Target for Chronic Pancreatitis in Pancreatic Autophagy Dysfunction-induced Mouse Model.**

Gyuwon Jeong, PhD — Stanford University, Stanford, CA

**A Distinct High-risk Subgroup of Complicated Acute Necrotizing Pancreatitis Qualify as Severe Pancreatitis: A Dual-Center Study of 1383 Patients.**

Soumya Jagannath Mahapatra, MD — All India Institute of Medical Sciences, New Delhi, India

## **Persistent Immune Activation and Remodeling in Pediatric Acute and Recurrent Pancreatitis After Single AP Episode**

Faizan Ahmed, PhD — Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

## **A Syndemic Perspective on Chronic Pancreatitis: Social Risk Burden, Health Status, and Healthcare Utilization in PROCEED**

Radmila Choate, PhD, MPH — University of Kentucky, Lexington, KY, USA

## **A Longitudinal Immune Atlas of Complicated Acute Pancreatitis Defines a Severity-Governing Axis and Early Predictive Signature**

Dan Xu, PhD — Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

### **Concurrent Session B | 2:45–4:15 pm**

#### **Abstract-Driven Session: Pancreatic Cancer**

##### **GPR81-Driven Synthetic Lethality in Diabetes-Associated Pancreatic Cancer**

Slavica Tudzarova, PhD — University of California, Los Angeles, Los Angeles, CA, USA

##### **Defining the Molecular Landscape and Therapeutic Management of Pancreatic Acinar Cell Carcinoma: An International Clinicogenomic Study**

Guoliang Qiao, MD, PhD — The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

##### **Precise STING Activation Driven by Tumor Antigen Leads to Effective PDAC Control via Reprogramming of the Tumor Microenvironment**

Zhongquan Cheng, PhD — The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China

##### **A Detailed Comparison of Pancreatic Cyst Fluid Analyses**

Mariela Trejo, MD — NYU Langone Health, New York, NY, USA

##### **Genetic deletion of MALL reprograms PDAC tumor microenvironment and improves efficacy of anti-PD1 therapy**

Somnath Pandey, PhD — University of Miami, Miami, FL

##### **PanCT Surgical Brief: An AI Pipeline for Automated Anatomy-Grounded Resectability Reporting from Pancreatic CT Scans**

Sri Harsha Boppana, MD — Nassau University Medical Center, East Meadow, NY, USA

##### **Clinical evaluation of ApoA2-isoforms compared with CA19-9 in surgically resectable pancreatic cancer**

Akira Matsushita, MD, PhD — Nippon Medical School, Tokyo, Japan

**4:15–4:45 pm**

**Coffee Break with Exhibitors**

### **Concurrent Session A | 4:45–5:45 pm**

#### **The Inflammatory Milieu in Pancreatitis**

**4:45–5:00 pm**

##### **The Role of Visceral Fat in Acute Pancreatitis**

Vijay Singh, MD | Mayo Clinic

**5:00–5:15 pm**

##### **Role of the Microbiome in Complications of Acute Pancreatitis**

Albrecht Neese, MD | University Medical Center Göttingen

**5:15–5:30 pm**

##### **Immunopathology of Recurrent Acute and Chronic Pancreatitis: What Have We Learned from Pancreas Tissue?**

Bomi Lee, PhD | Stanford University, CA.

**5:30–5:45 pm**

**The Role of IL-6 vs. Other Mediators in Progression of Acute and Chronic Pancreatitis**

Jami Saloman, PhD | University of Pittsburgh, Pittsburgh, PA

**5:45–6:00 pm**

**Q&A Discussion**

**Concurrent Session B | 4:45–6:00 pm**

**Feeding the Beast: Exploiting the Metabolic Weakness of Pancreatic Cancer.**

**4:45–5:00 pm**

**Growing Hope: How Patient-Derived Organoids Are Reshaping Pancreatic Cancer Research.**

Danielle Engle, PhD | Salk Institute

**5:00–5:15 pm**

**Isocitrate Dehydrogenase 1 is a Metabolic Vulnerability for Pancreatic Cancer**

Jordan Winter, MD | Case Western Reserve University

**5:15–5:30 pm**

**Friends, Foes, and Fuel: Metabolic Alliances Within the Tumor Microenvironment**

Chris Halbrook, PhD | University of California, Irvine, Irvine, CA

**5:30–5:45 pm**

**Mechanisms of KRAS-Driven Pancreatic Tumorigenesis**

Howard Crawford, PhD | Henry Ford Health, Detroit, MI

**5:45–6:00 pm**

**Rewiring the Metabolic Ecosystem of Pancreatic Cancer: From Metabolic Dependencies to Therapeutic Vulnerabilities**

Jing Xue, MD, PhD | Renji Hospital, Shanghai Jiao Tong University

**6:00–6:45 pm**

**REPRESENTATION MATTERS: A Panel Discussion**

**Moderators:** Sohail Husain, MD (Stanford University, Stanford, CA) & Anne Marie Lennon, MD, PhD (U Pittsburgh Medical Center)

**Panelists:** Anne Marie Lennon, MD, PhD | U Pittsburgh Medical Center, Melena Bellin, MD | University of Minnesota, Minneapolis, MN & Anil Rustgi, MD | Columbia University, New York, NY

**6:45–7:45 pm**

**Reception**

**Saturday, December 12, 2026**

**7:00–8:00 am**

**Breakfast**

**Concurrent Session A | 8:00–9:15 am**

**Inflammation, Immune Microenvironment, and Interception in Pancreatic Cancer**

**8:00–8:15 am**

**Pancreatic Cancer-Associated Fibroblasts and Extracellular Matrix**

Eti Cukierman, PhD | Fox Chase Cancer Center

**8:15–8:30 am**

**Persistence of the Fetal Splanchnic Program in Pancreatic Cancer-Associated Fibroblasts**

Lu Han, PhD | Medical University of South Carolina

**8:30–8:45 am**

**Metabolism in the Tumor Microenvironment: Pancreatic Primary Tumor and Liver Metastases**

Shuichi Aoki, MD, PhD | University of Tokyo, Tokyo, Japan

**8:45–9:00 am**

**Tolerogenic Immune Microenvironment: Myeloid Cells**

Ghulam Manji, MD, PhD | Columbia University, New York, NY

**9:00–9:15 am**

**Determinants of B Cell Function in Pancreatic Cancer**

Yuliya Pylayeva-Gupta, PhD | UNC Lineberger Comprehensive Cancer Center

**Concurrent Session B | 8:00–9:15 am**

**Hot Topics in Pancreatitis: The Edge of Discovery**

**8:00–8:15 am**

**The Long Road Begins Early: Disease Progression in Pediatric Pancreatitis**

Emily Perito, MD | UCSF, San Francisco, CA

**8:15–8:30 am**

**Chronic Pancreatitis Pain: Demystifying the Mind-Body Connection**

Laurie Keefer, PhD | Icahn School of Medicine at Mount Sinai, New York, NY

**8:30–8:45 am**

**From Sight to Stats: Imaging-Based Diagnosis of Fatty Pancreas**

Temel Tirkes, MD | Indiana University School of Medicine, Indianapolis, IN

**8:45–9:00 am**

**Lessons from the East: How Asian Clinical Trials are Reshaping Pancreatitis Care**

Lu Ke, MD, PhD | Nanjing University, Nanjing, China

**9:00–9:15 am**

**Q&A Discussion**

**9:15–10:30 am**

**Controversies in Clinical Pancreatology: Cholecystectomy for Idiopathic Acute Pancreatitis — Save the Gallbladder or the Pancreas?**

**9:15–9:25 am**

**Top Abstract Aligning with This Session**

**9:25–9:45 am**

**PRO: Cholecystectomy Should Be Performed in Idiopathic Acute Pancreatitis**

Santhi Vege, MD | Mayo Clinic, Rochester, MN

**9:45–10:05 am**

**CON: Cholecystectomy Should Not Be Performed in Idiopathic Acute Pancreatitis**

Saurabh Chawla, MD | Emory University, Atlanta, GA

**10:05–10:30 am**

**Discussion and Controversies Forum**

**10:30–11:00 am**

**Coffee Break with Exhibitors**

**Rapid Research: Abstracts in Action | 11:00 am–1:00 pm**

11:00–11:05 am

## Session Introduction

20 abstracts presented in 5 minutes (3 min presentation plus 2 min Q&A)

### **The Effects of Sulfuretin on Pancreatitis.**

Sung-Joo Park, MD, PhD — School of Korean Medicine, Wonkwang University, Iksan, Republic of Korea

### **CCL18<sup>+</sup> Tumor-Associated Macrophages Driving Immune Checkpoint Therapy Resistance in Pancreatic Cancer by Remodeling the Immune Microenvironment through Enhancing BCL9-Dependent Tumor Stemness.**

Fuming Xie, MD — Chongqing General Hospital, Chongqing, China

### **Novel triglyceride-lowering therapies to reduce the risk of acute pancreatitis in severe hypertriglyceridemia: a systematic review and meta-analysis.**

Yongzi Wu, MD — West China Hospital, Sichuan University, Chengdu, Sichuan, China

### **Clinical Impact of Cyst Fluid Next-Generation Sequencing in Pancreatic Cysts: A Single-Center Cohort Study**

Tareq Alsaleh, MD — AdventHealth Orlando, Orlando, FL, USA

### **Pharmacologic NRF2 Activation Ameliorates Pancreatitis Associated with Lipoprotein Lipase Insufficiency.**

Olga A. Mareninova, PhD — David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, CA, USA

### **Therapy induces a regenerative stromal niche that enforces tumor stemness in PDAC.**

Jingjing Qi, PhD — Department of Biliary-Pancreatic Surgery, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

### **Beyond Disease Severity: Digital Phenotyping of Sleep Health Using Fitbit Wearables in the All of Us Research Program.**

Ketrell McWhorter, PhD, MBA — University of Kentucky, Lexington, KY, USA

### **Appleby operation (DP-CAR) for pancreatic cancer: High risk of Stomach Ischemia**

Vera Oliveira, MD — Botton-Champalimaud Pancreatic Cancer Centre, Lisbon, Portugal

### **Metabolic profiling reveals a GS-driven immunometabolic and glyco-immune regulatory axis underlying macrophage polarization and chronic pancreatitis fibrosis with translational validation.**

Kailin Jiang, MD, PhD — Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

### **Evaluation of ferroptosis as a biomarker to predict treatment outcomes of cancer immunotherapy.**

Yang Cai, PhD — Department of Medicine, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA

### **Retrospective Analysis of Clinical Characteristics and Pancreatic Disease Outcomes in Patients with Severely Elevated Triglyceride Levels in an Integrated Healthcare System.**

Bechien Wu, MD, MPH — Arrowhead Pharmaceuticals, Pasadena, CA, USA

### **Safety, immunogenicity, and early outcomes of personalized cancer vaccine combined with Tislelizumab and GemCap in resectable pancreatic cancer.**

Yunwei Sun, MS — West China Hospital of Sichuan University, Chengdu, Sichuan, China

### **A distinct cholesterol hydrolysis state licenses EGFR-driven symbiotic tumor-macrophage niche formation at the invasive boundary of pancreatic cancer.**

Guangfu Wang, PhD — The First Affiliated Hospital with Nanjing Medical University, Nanjing, Jiangsu, China

### **CGRP Antagonist Exposure Is Associated with Reduced Need for Pancreatic Surgery in Chronic Pancreatitis: A Multi-Center Propensity Score-Matched Cohort Study.**

Nikhil Bush Jayaram, MD — University of Alabama at Birmingham, Birmingham, AL, USA

**Potential utility of ApoA2-i for biomarker-guided risk-adapted pancreatic cancer screening.**

Kazufumi Honda, DDS, PhD — Nippon Medical School, Tokyo, Japan

**Spermine dampens histone crotonylation to trigger angiogenesis driving very early metastasis of pancreatic cancer.**

Lianjing Cao, PhD — Department of Hepatobiliary Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

**Vitamin B12 and Food Folate Intake and Pancreatic Ductal Adenocarcinoma Risk: Findings from a matched case-control study.**

Shuang Li, MD, PhD — University of Pittsburgh, Pittsburgh, PA

**BHLHE40 defines an immunosuppressive myofibroblastic cancer-associated fibroblast (myCAF) state in pancreatic ductal adenocarcinoma**

Kamalpreet Kaur Sandha, PhD — Department of Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA

**Gemcitabine/Nab-Paclitaxel-Resistant Pancreatic Cancer Exhibits Transcriptional Reprogramming, Increased CD8+ T-Cell Infiltration, and Reduced KRAS Inhibitor Sensitivity**

Meet Patel, MS — The University of Alabama at Birmingham

**Multi-site External Validation of An Agentic AI Workflow for Accurate Pancreatic Ductal Adenocarcinoma Cohort Identification**

Anup Kumar Mishra, PhD, MS — Mayo Clinic, Rochester, MN, USA

**White adipose tissue-derived IL-6 exacerbates acute pancreatitis in obesity.**

Maria E. Moreno-Fernandez, PhD — Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA

**1:00 pm**

**Annual Meeting Concludes**